EXHIBIT 10.2

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE SYNTHORX, INC. HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO SYNTHORX, INC. IF
PUBLICLY DISCLOSED.

CONFIDENTIAL

FIFTH AMENDMENT
to
RESEARCH FUNDING AND OPTION AGREEMENT

This Fifth Amendment (“Fifth Amendment”), entered into and made effective as of
the last dated signature below (“Fifth Amendment Effective Date”), is made to
RESEARCH FUNDING AND OPTION AGREEMENT dated July 31st, 2014, as amended on
September 25, 2015, September 9, 2016, October 16, 2017, and August 16, 2018
(collectively, the “Agreement”) by and between THE SCRIPPS RESEARCH INSTITUTE, a
California nonprofit public benefit corporation (“TSRI”), and SYNTHORX, INC., a
Delaware corporation (“Sponsor”). Capitalized terms used but not defined herein
shall have the same meanings set forth in the Agreement.

WHEREAS, the Parties desire to make certain amendments to the Agreement under
the terms and conditions contained herein;

NOW, THEREFORE, TSRI and Sponsor agree as follows:

1.

TSRI and Sponsor acknowledge and agree that the Agreement has been in full force
and effect continuously beginning with the Effective Date and shall continue in
full force and effect through the date set forth in Section 7.1 of the Agreement
(as amended hereby).

2.

Pursuant to Article 3 of the Agreement, including Section 3.4, Sponsor hereby
delivers written notice to TSRI that it is exercising the Option to all Patent
Rights and TSRI Technology and TSRI’s interest in any Joint Technology, if any,
existing as of the Fifth Amendment Effective Date and the subject matter of all
such Patent Rights, TSRI Technology and Joint Technology is exclusively licensed
by TSRI to Sponsor under the Exclusive License Agreement (entered into by and
between TSRI and Sponsor on July 31, 2014, as amended).

3.

Section 1.2 of the Agreement shall be deleted in its entirety and replaced as
follows:

 

“1.2

Agreement Number. The original Agreement has been assigned TSRI agreement number
2014-0475, the first amendment has been assigned TSRI agreement number
2015-0949, the second amendment has been assigned TSRI agreement number
2016-0927, the third Amendment has been assigned TSRI agreement number
2017-0685, the fourth amendment has been assigned TSRI agreement number
2018-0769, and this Fifth Amendment has been assigned TSRI agreement number
2019-0361.”

4.

Article 1 is hereby amended by adding Section 1.13 as follows:

“1.13Research Investigators.  The term “Research Investigators” shall mean each
of the following individuals:

Name

Title

[***]

[***]

[***]

[***]

[***]

[***]

 

Page 1 of 5

 

--------------------------------------------------------------------------------

 

And such other TSRI personnel as may from time-to-time work on the Research
Program, as defined in the original Agreement and any amendments thereto.

5.

Section 2.4 of the Agreement is amended by adding Section 2.4(d) as follows:

“d.Support of Research Investigators.  TSRI hereby represents and warrants to
Sponsor that the funding set forth herein, beginning with the 21st payment and
ending with the 28th payment, shall be used solely to support the activities of
the Research Investigators in the conduct of the Research Program and for no
other purpose.  TSRI agrees that if a Research Investigator stops performing
work on the Research Program prematurely, then TSRI shall refund to Sponsor that
portion of the relevant payment that would have been allocated to support that
Research Investigator’s work on the Research Program.  TSRI further agrees to
promptly inform Sponsor in writing when none of the Research Investigators are
performing work on the Research Program.”  

6.

Section 2.4 (a) of the Agreement shall be revised to add the following payments
to the payment schedule:

21st payment

due: [***]

amount (USD): $[***]

22nd payment

due: [***]

amount (USD): $[***]

23rd payment

due: [***]

amount (USD): $[***]

24th payment

due: [***]

amount (USD): $[***]

25th payment

due:  [***]

amount (USD): $[***]

26th payment

due:  [***]

amount (USD): $[***]

27th payment

due:  [***]

amount (USD): $[***]

28th payment

due:  [***]

amount (USD): $[***]

 

7.

Section 7.1 shall be deleted in its entirety and replaced as follows:

 

“7.1

Term. Unless terminated sooner, the initial term of this Agreement shall
commence on the Effective Date and shall continue until the earlier of (a) July
31, 2022, and (b) the completion of the Research Program (through and including
the publication of any manuscripts attendant to the Research Program), in each
case unless extended by written mutual agreement of the parties.”

8.

Section 9.9 of the Agreement is hereby amended by deleting the address for
Sponsor and replacing it as follows:

“FOR SPONSOR:

Synthorx, Inc.

11099 Torrey Pines Road, Suite 190

La Jolla, CA 92037

Attention:  President & Chief Executive Officer”

 

Page 2 of 5

--------------------------------------------------------------------------------

 

9.

The Research Program in Exhibit A of the Agreement shall be expanded by the
research described in Exhibit A-1 below.

 

Except as expressly set forth herein, all the terms and provisions of the
Agreement shall remain in full force and effect.

 

 

 

 

[Signatures appear on the following page]

Page 3 of 5

--------------------------------------------------------------------------------

 

In WITNESS WHEREOF, the Parties have executed this Fifth Amendment by their duly
authorized representatives as of the last date set forth below.

 

 

TSRI:                                                                  

THE SCRIPPS RESEARCH INSTITUTE  

 

 

By: /s/ Matthew Tremblay         
                                                

Name: Matthew Tremblay

Title: Chief Operating Officer

Date: July 31, 2019

Sponsor:

SYNTHORX, INC.

 

 

By: /s/ Laura Shawver                                                          

Name: Laura Shawver

Title: President and CEO

Date: July 31, 2019

 

 

 

Page 4 of 5

--------------------------------------------------------------------------------

 

 

Exhibit A-1

 

[***]

Page 5 of 5